BioCentury | Mar 15, 2010
Clinical News

NMP22 BladderChek Test: Post-marketing study data

...NMP22 BladderChek Test confirmed by FISH; $10,267 for cystoscopy plus cytology; $11,143 for cystoscopy plus NMP22...
...Inverness Medical Innovations Inc. (NYSE:IMA), Waltham, Mass. Product: NMP22 BladderChek Test Business: Diagnostic Molecular target: NMP22...
BioCentury | Sep 3, 2007
Company News

Inverness, Matritech deal

...deal was announced. MZT also is eligible for $2 million in revenue milestones. MZT markets NMP22...
BioCentury | Jan 23, 2006
Clinical News

NMP22 BladderChek Test diagnostic data

...In a U.S. trial in 668 patients with a history of bladder cancer, NMP22 assay in...
...87.3%, respectively. Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Test Business: Diagnostic Molecular target: NMP22...
BioCentury | Jul 18, 2005
Clinical News

NMP22 BladderChek Test regulatory update

...received Japanese marketing approval for NMP22 BladderCheck test, an assay to detect nuclear matrix protein NMP22...
...BladderChek is approved in the U.S., Europe and Canada. Matritech Inc. (MZT), Newton, Mass. Product: NMP22...
BioCentury | Feb 21, 2005
Clinical News

NMP22 BladderChek Test diagnostic data

...In a U.S. study in 1,331 patients at risk for bladder cancer, the NMP22 BladderChek test...
...89% seen by cytoscopy alone (p=0.26). Of the 79 patients diagnosed with bladder cancer, the NMP22...
...Medical Association. Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Test Business: Diagnostic Molecular target: NMP22...
BioCentury | Sep 27, 2004
Clinical News

NMP22 BladderChek regulatory update

...Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Business: Diagnostic Health Canada approved NMP22 BladderChek, an...
...BladderChek Business: Diagnostic Health Canada approved NMP22 BladderChek, an assay to detect nuclear matrix protein NMP22...
BioCentury | Jun 14, 2004
Company News

Matritech, Inverness sales and marketing update

...to hospitals and clinical reference laboratories in the U.S. MZT will continue to sell the NMP22...
...own sales force. NMP 22 is a microplate enzyme immunoassay that detects elevated levels of NMP22...
BioCentury | Feb 23, 2004
Clinical News

NMP22 BladderCheck test regulatory update

...detect the bladder cancer matrix protein NMP22 in urine. Matritech Inc. (MZT), Newton, Mass. Product: NMP22...
BioCentury | Oct 27, 2003
Company News

Matritech, Stellar International Inc. deal

...Canadian specialty pharma company SSY received exclusive rights to market NMPS's NMP22 BladderChek test to diagnose...
BioCentury | Oct 24, 2003
Company News

Stellar, Matritech bladder diagnostic deal

...Canadian specialty pharma company Stellar (TSE:YYS; SLRXF) received exclusive rights to market NMPS's NMP22 BladderChek test...
Items per page:
1 - 10 of 66